Skip to main content

Advertisement

Table 4 Comparison of the sample sizes and joinpoint estimates, presented with 95% confidence intervals, for all analyses

From: What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink

  Probable AD Any AD Any dementia
Source Main analysis Additional file 3 Additional file 3
Diagnoses Probable AD Probable AD
Possible AD
Probable AD
Possible AD
Non-AD and mixed dementias
AChE inhibitors Eligible: 10,456
Treated: 5019
Joinpoint 1: Oct 2012
(Sep 2011–Apr 2013)
Joinpoint 2: May 2013
(Nov 2012–Apr 2014)
Eligible: 21,342
Treated: 6449
Joinpoint 1: Jun 1999
(Apr 1998–Dec 2000)
Joinpoint 2: Jun 2001
(Sep 2000–Mar 2002)
Eligible: 38,650
Treated: 9896
Joinpoint 1: Aug 2000
(Jun 1998–Nov 2000)
Joinpoint 2: Jan 2001
(Sep 2000–Nov 2001)
NMDA receptor antagonists Eligible: 9964
Treated: 1052
Joinpoint 1: Mar 2011
(Aug 2010–Apr 2011)
Joinpoint 2: Jun 2011
(Apr 2011–Nov 2011)
Eligible: 18,930
Treated: 1309
Joinpoint 1: Sep 2010
(Dec 2009–Apr 2011)
Joinpoint 2: Nov 2011
(Apr 2011–Mar 2012)
Eligible: 35,625
Treated: 1961
Joinpoint 1: Aug 2010
(Nov 2009–Dec 2010)
Joinpoint 2: Nov 2011
(Aug 2011–Mar 2012)
  1. AChE Acetylcholinesterase, AD Alzheimer’s disease, NMDA N-methyl-d-aspartate